POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION

1 ( S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide represented by formula (I) in crystalline form

2 . A crystalline form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide, having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06, 19.28 and 19.97.

3 . The crystalline form according to claim 2 having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06 and 19.97.

4 . The crystalline compound of formula (I) according to claim 2 , having an average particle size value (D 50 ) in the range from about 1 µm to about 20 µm.

5 . The crystalline compound of formula (I) according to claim 2 , having an average particle size value (D 50 ) in the range from about 1 µm to about 10 µm.

6 . The crystalline compound of formula (I) according to claim 2 , having D 90 value in the range from about 3 µm to about 100 µm.

7 . The crystalline compound of formula (I) according to claim 2 , having D 90 value in the range from about 3 µm to about 50 µm.

8 . The crystalline compound of formula (I) according to claim 2 , having purity greater than about 99% by HPLC.

9 . The crystalline compound of formula (I) according to claim 2 , is in substantially pure crystalline form.

10 . S-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide in amorphous form.

11 . A process for preparation of the crystalline form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl) acetamide, having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06, 19.28 and 19.97 comprising,

i) treating (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide of compound formula (I) with a solvent;

ii) heating the reaction mass to get clear solution and gradually cooling and

iii) isolating the solid.

12 . The process according to claim 11 , wherein a solvent is selected from the group consisting of acetonitrile, ethyl acetate, methanol, ethanol, isopropanol acetonitrile, acetone, methyl acetate, acetic acid, ethylene glycol and 1,4-dioxane.

13 . A process for preparation of the crystalline form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide, having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06, 19.28 and 19.97 comprising,

i) treating (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide of compound formula (I) with a solvent to get a clear solution;

ii) adding an anti-solvent and

iii) isolating the solid.

14 . The process according to claim 13 , wherein a solvent is selected from the group consisting of acetonitrile, methanol, acetone, THF, toluene, Methyl ethyl ketone, and ethyl acetate.

15 . The process according to claim 13 , wherein an anti-solvent is selected from the group consisting of diisopropyl ether, hexane, methyl tert. butyl ether and methanol.

16 . A process for preparation of the crystalline form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide, having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06, 19.28 and 19.97 comprising,

i) treating (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide of compound formula (I) with a solvent to get a clear solution;

ii) adding water and

iii) isolating the solid.

17 . The process according to claim 16 , wherein a solvent is selected from the group consisting of N-methyl-2-pyrrolidone, THF, acetone, methanol, dimethylacetamide, dimethylformamide, 1-4 dioxane and methyl ethyl ketone.

18 . A process for preparation of the compound (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide (compound of formula (I)) or its pharmaceutically acceptable salt thereof, the process comprising the step of:

(a) reacting compound of formula (II)

with compound of formula (III)

(b) optionally converting compound of formula (I) to its pharmaceutically acceptable salt.

19 . The process according to claim 18 , wherein the reaction between compound of formula (II) and compound of formula (III) is carried out in the presence of tetramethyluronium tetrafluoroborate (TBTU) or 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU).

20 . A process for preparation of the crystalline form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl)pyrazin-2-yl)phenyl) acetamide, having a characteristic X- ray diffraction pattern comprising of the peaks expressed in terms of 2θ ±0.2: 11.22, 12.01, 15.88, 18.06, 19.28 and 19.97 comprising,

(a) reacting compound of formula (II)

with compound of formula (III)

(b) treating (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide obtained in step (a) with a solvent;

(c) heating the reaction mass to get clear solution and gradually cooling and

(d) isolating the solid.

21 . The process according to claim 20 wherein in step (b) a solvent is selected from acetonitrile, ethyl acetate, methanol, ethanol, isopropanol acetonitrile, acetone, methyl acetate, acetic acid, ethylene glycol and 1,4-dioxane.

22 . A process for preparation of the amorphous form of (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide of compound formula (I) comprising,

(a) heating (S)-2-(4-(1,1-difluoro-2-hydroxypropyl)phenyl)-N-(4-(3-(2-ethylphenyl) pyrazin-2-yl)phenyl) acetamide of compound formula (I) to melt under vacuum; and

(b) cooling the step (a) product.